MX2013008074A - Combinacion. - Google Patents

Combinacion.

Info

Publication number
MX2013008074A
MX2013008074A MX2013008074A MX2013008074A MX2013008074A MX 2013008074 A MX2013008074 A MX 2013008074A MX 2013008074 A MX2013008074 A MX 2013008074A MX 2013008074 A MX2013008074 A MX 2013008074A MX 2013008074 A MX2013008074 A MX 2013008074A
Authority
MX
Mexico
Prior art keywords
methyl
human
relates
treatment
thiophenecarboxamide
Prior art date
Application number
MX2013008074A
Other languages
English (en)
Other versions
MX356704B (es
Inventor
Rakesh Kumar
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MX2013008074A publication Critical patent/MX2013008074A/es
Publication of MX356704B publication Critical patent/MX356704B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con un método para tratar el cáncer en un humano y con combinaciones farmacéuticas útiles en tal tratamiento; en particular, el método se relaciona con un método de tratamiento del cáncer, que incluye administrar un compuesto que inhibe el proteasoma, y la N-{(1S)-2-amino-1-[(3-flu orofenil)metil]etil}-5-cloro-4-(4-cloro-1-metil-1H-pirazol-5-il)- 2-tiofencarboxamida, o una sal farmacéuticamente aceptable de la misma, y agentes antineoplásicos adicionales opcionales, a un humano en necesidad del mismo.
MX2013008074A 2011-01-11 2012-01-11 Combinación. MX356704B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161431508P 2011-01-11 2011-01-11
PCT/US2012/020863 WO2012097021A1 (en) 2011-01-11 2012-01-11 Combination

Publications (2)

Publication Number Publication Date
MX2013008074A true MX2013008074A (es) 2013-08-09
MX356704B MX356704B (es) 2018-06-11

Family

ID=46507420

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008074A MX356704B (es) 2011-01-11 2012-01-11 Combinación.

Country Status (15)

Country Link
US (6) US20130288984A1 (es)
EP (1) EP2663189B1 (es)
JP (1) JP6100700B2 (es)
KR (1) KR20140053836A (es)
CN (1) CN103298345B (es)
AU (1) AU2012205601B2 (es)
BR (1) BR112013017722A2 (es)
CA (1) CA2824201A1 (es)
EA (1) EA029000B1 (es)
ES (1) ES2689760T3 (es)
IL (1) IL227097B (es)
MX (1) MX356704B (es)
SG (2) SG10201600077RA (es)
WO (1) WO2012097021A1 (es)
ZA (1) ZA201304139B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2016116915A (ru) * 2013-10-01 2017-11-13 Новартис Аг Комбинация
KR20160070188A (ko) * 2013-11-07 2016-06-17 데시페라 파마슈티칼스, 엘엘씨. 암치료에 유용한 tie2 키나아제의 억제 방법
CN111818915B (zh) 2018-01-31 2024-05-24 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
KR20220045189A (ko) 2019-08-12 2022-04-12 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양을 치료하는 방법
EP4327827A3 (en) 2019-12-30 2024-05-29 Deciphera Pharmaceuticals, LLC Amorphous kinase inhibitor formulations and methods of use thereof
JP2023509628A (ja) 2019-12-30 2023-03-09 デシフェラ・ファーマシューティカルズ，エルエルシー １－（４－ブロモ－５－（１－エチル－７－（メチルアミノ）－２－オキソ－１，２－ジヒドロ－１，６－ナフチリジン－３－イル）－２－フルオロフェニル）－３－フェニル尿素の組成物
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6328590B1 (en) 2000-07-20 2001-12-11 Emc Corporation Methods and apparatus for controlling attachment of an electronic module with a circuit board connector
US7468371B2 (en) * 2004-03-24 2008-12-23 Abbott Laboratories Inc. Tricyclic pyrazole kinase inhibitors
CA2584246C (en) 2004-10-13 2011-08-09 Pharmacia & Upjohn Company Llc Crystalline forms of 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6h)-yl]-n-(2-hydroxyethyl)-4-methylbenzamide
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
JP2009506069A (ja) * 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP1840114A1 (en) 2006-03-30 2007-10-03 LTB4 Sweden AB Crystalline Leukotriene B4
CN101415411A (zh) 2006-04-05 2009-04-22 诺瓦提斯公司 用于治疗癌症的治疗剂组合
WO2007122686A1 (ja) 2006-04-14 2007-11-01 Eisai R & D Management Co., Ltd. ベンズイミダゾール化合物
CA2661422C (en) 2006-08-25 2017-06-27 Cougar Biotechnology, Inc. Methods and compositions for treating cancer
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
JP4299327B2 (ja) 2006-08-31 2009-07-22 トヨタ自動車株式会社 可変バルブタイミング装置
WO2008094321A2 (en) 2006-10-04 2008-08-07 Universtiy Of South Florida Akt sensitization of cancer cells
KR101508017B1 (ko) 2006-10-13 2015-04-08 바스프 에스이 2-클로로-5-［3,6-디히드로-3-메틸-2,6-디옥소-4-(트리플루오로-메틸)-1-(2ｈ)-피리미디닐］-4-플루오로-ｎ-［［메틸-(1-메틸에틸)-아미노］술포닐］벤즈아미드의 수화물
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
AU2008309383B2 (en) 2007-10-11 2012-04-19 Astrazeneca Ab Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors
WO2009067453A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
DE102008044901A1 (de) 2008-08-29 2010-03-04 Siemens Aktiengesellschaft Verfahren und Vorrichtung zur Auswahl eines Bestrahlungsplans sowie Bestrahlungsanlage
US20110288142A1 (en) 2009-01-30 2011-11-24 Chen Pingyun Y CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
CA2765983C (en) 2009-06-26 2017-11-14 Novartis Ag 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
US8796298B2 (en) 2009-10-08 2014-08-05 Glaxosmithkline Llc Combination of a B-Raf inhibitor: N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1- dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide and the Akt inhibitor: N-{ (1S)-2-amino-1-[(3- fluorophenyl)methyl]ethyl}-5-chIoro-4-(4-chIoro- 1 -methyl- 1 H-pyrazol-5-yl)-2-10 thiophenecarboxamide useful in the treatment of cancer
CN103857395A (zh) 2011-04-01 2014-06-11 基因泰克公司 Akt抑制剂化合物和阿比特龙的组合及使用方法
AU2012250650A1 (en) 2011-05-03 2013-11-14 University Of Rochester Methods for treating prostate cancer
WO2013010136A2 (en) 2011-07-13 2013-01-17 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
CN104066744B (zh) 2011-10-10 2017-03-22 扎克系统公司 用于制备17‑取代的甾体的方法
AU2012321110B2 (en) 2011-11-30 2014-10-23 Astrazeneca Ab Combination treatment
CA3015208C (en) 2012-06-04 2024-01-02 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
EP3052098B1 (en) 2013-10-01 2020-12-02 Novartis AG Enzalutamide in combination with afuresertib for the treatment of prostate cancer

Also Published As

Publication number Publication date
AU2012205601A1 (en) 2013-08-01
JP6100700B2 (ja) 2017-03-22
US20150119337A1 (en) 2015-04-30
CN103298345A (zh) 2013-09-11
EA201391027A1 (ru) 2014-01-30
CA2824201A1 (en) 2012-07-19
EP2663189A4 (en) 2014-06-11
ES2689760T3 (es) 2018-11-15
US10449226B2 (en) 2019-10-22
JP2014507412A (ja) 2014-03-27
ZA201304139B (en) 2014-02-26
US20170100449A1 (en) 2017-04-13
EP2663189B1 (en) 2018-07-04
BR112013017722A2 (pt) 2016-07-12
US20160022641A1 (en) 2016-01-28
KR20140053836A (ko) 2014-05-08
US20120258933A1 (en) 2012-10-11
MX356704B (es) 2018-06-11
AU2012205601B2 (en) 2016-03-24
SG191724A1 (en) 2013-08-30
IL227097B (en) 2018-02-28
EP2663189A1 (en) 2013-11-20
WO2012097021A1 (en) 2012-07-19
EA029000B1 (ru) 2018-01-31
US20160375086A1 (en) 2016-12-29
CN103298345B (zh) 2016-12-14
US20130288984A1 (en) 2013-10-31
SG10201600077RA (en) 2016-02-26

Similar Documents

Publication Publication Date Title
MX356704B (es) Combinación.
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
PH12016502355B1 (en) Pharmaceutical composition
PH12015502628A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
MX2020002150A (es) Terapia de combinación para el tratamiento del cáncer.
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX2014010590A (es) Terapia de combinacion para trastornos proliferativos.
MY179607A (en) Combinations of akt inhibitor compounds and abiraterone, and methods of use
MX2014003180A (es) Metodos para tratar vhc.
MX2015017201A (es) Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga.
GB201118656D0 (en) New compounds
WO2016133903A3 (en) Combination therapy for cancer treatment
IN2014DN10670A (es)
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
PH12016502352A1 (en) Pharmaceutical composition
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
TW201613578A (en) Pharmaceutical combinations
EA201491427A1 (ru) Замещенные фенилимидазопиразолы и их применение
PH12015500111A1 (en) Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
MX366309B (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
MX368640B (es) Composición farmacéutica para tratar inflamación y dolor.
MX368641B (es) Compuestos para el tratamiento de inflamación y dolor.
MX2014013491A (es) Metodos para mantener, tratar o mejorar la funcion cognitiva.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: NOVARTIS AG

FG Grant or registration